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A B S T R A C T
This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows:
To assess the diagnostic test accuracy of the Addenbrooke’s Cognitive Examination-III (ACE-III) and the mini-ACE, for the screening
of all-cause dementia, dementia subtypes (Alzheimer’s disease, vascular dementia, frontotemporal dementia, Lewy body dementia), and
mild cognitive impairment, across all healthcare settings at all prespecified thresholds.
B A C K G R O U N D
Dementia is an emerging public health concern; 46 million peo-
ple currently live with dementia worldwide (Alzheimer’s Society
2016). As the population ages, this figure is only expected to rise
further, and thus sensitive screening tests are becoming increas-
ingly important to distinguish healthy older adults from those
with early cognitive impairment (Alzheimer’s Society 2016; Prince
2015). Early identificationof peoplewith dementia is important to
facilitate the early introduction of current available therapies, and
to instigate important holistic patient and carer support through
the provision of allied health professional and support services
(Aminzadeh 2007; de Vugt 2013). Therefore, sensitive screening
tests are required to support early referral for specialist assessment
and management. The Addenbrooke’s Cognitive Examination-III
(ACE-III), and its shorter counterpart, the mini-ACE, are two
such cognitive screening tests that arewidely available for use across
a variety of healthcare settings (Hsieh 2013; Hsieh 2015). The
ACE-III and mini-ACE have reported good sensitivity and speci-
ficity in the literature (Hsieh 2013;Hsieh 2015), but, to date, have
not been included in systematic reviews or meta-analyses. In this
review we will evaluate the validity of the mini-ACE and ACE-III
to screen for dementia and mild cognitive impairment across all
healthcare settings.
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Target condition being diagnosed
Dementia currently affects 850 000 people in the UK alone, and
this is projected to rise by 40% over the next decade as the popu-
lation ages (Alzheimer’s Society 2016). Dementia is characterised
by a progressive loss of memory or cognitive function, resulting in
impaired ability to perform activities of daily living (Creavin 2016;
Davis 2015). The most typical presentation of dementia is that
of progressive memory loss. However, dementia can present in a
multitude of ways, from language deficits to loss of executive func-
tioning (Robinson 2015). Dementia is an over-arching term that
encompasses several forms, including Alzheimer’s disease, vascu-
lar dementia, frontotemporal dementia and Lewy body dementia
(Robinson 2015). As knowledge and understanding has evolved, it
has become increasingly difficult to distinguish between these de-
mentia subtypes, as there is considerable clinical and pathological
overlap between them (Attems 2014; Mandal 2006). Alzheimer’s
disease is the most common dementia subtype, accounting for
62% of all cases (Alzheimer’s Society 2016). Alzheimer’s disease
is notably characterised by the development of amyloid plaques,
tau deposits, and neurofibrillatory tangles, resulting in a progres-
sive deterioration in cognitive function (Takahashi 2017). Vascu-
lar dementia is the second most common form, comprising 17%
of all dementia cases (Alzheimer’s Society 2016). It is associated
with vascular risk factors and events (i.e. transient ischaemic at-
tack, acute stroke), resulting in chronic small vessel disease and
leading to sustained cerebral hypoperfusion and thus cognitive
impairment (Dichgans 2017). Deterioration in cognitive function
would characteristically result in a step-wise decline in cognition,
although a slow progression similar to that seen with Alzheimer’s
disease is also seen in vascular dementia secondary to small vessel
disease, rather than discrete vascular events (Dichgans 2017). Ten
per cent of dementia is mixed between subtypes, and the remain-
der is comprised of rarer forms: frontotemporal (2%), Parkinson’s
disease (2%), and Lewy body dementia (4%) (Alzheimer’s Society
2016). It is important to distinguish between these dementia sub-
types as this can affect both the approach to diagnosis and treat-
ment. Furthermore, identifying and stratifying the subtypes of de-
mentia allows therapies to be tailored on an individual and per-
sonalised basis. Acetylcholinesterase inhibitors and N-methyl-D-
aspartate (NMDA) receptor antagonists are now established ther-
apies for the treatment of mild to moderate Alzheimer’s disease
(NICE2011). The evidence base for the use of acetylcholinesterase
inhibitors in vascular dementia is considerably smaller, however,
the use of donepezil and rivastigmine are supported in a number
of Cochrane Reviews (Birks 2013; Malouf 2004).
Mild cognitive impairment (MCI) is an emerging concept, where
patients exhibit subjective and objective evidence of cognitive
decline, but importantly, their functional status is maintained
(Petersen 2004). Up to 60% of people with MCI will develop de-
mentia by ten years (Korolev 2016; Petersen 2004). However, it is
unclear why 40% of people withMCI do not progress to dementia
(Korolev 2016; Petersen 2004). Therefore, tools that can identify
and distinguish MCI, and predict those that are likely to develop
dementia in the future, are becoming increasingly important for
patients, clinicians, and researchers (Petersen 2004).
Index test(s)
Despite the emergence of a number of novel biomarkers, the de-
tection and diagnosis of dementia remains to be achieved by thor-
ough clinical assessment, and exclusion of important, potential re-
versible causes of cognitive decline (HealthQuality Ontario 2014;
Panegyres 2016; Robinson 2015). Cognitive assessment tools are
a key component of this process, and allow physicians to identify
not only the presence of cognitive impairment, but the severity,
and key cognitive domains affected (Panegyres 2016; Velayudhan
2014). Radiological and biochemical investigations are adjunctive
in the assessment of dementia, and are primarily used to exclude
important structural and reversible causes of cognitive decline,
i.e. tumours, hydrocephalus, and subdural haematoma (Harper
2014; Health Quality Ontario 2014; Panegyres 2016). Patholog-
ical changes (such as hippocampal atrophy and small vessel dis-
ease) are identified on brain imaging, but formal cognitive test-
ing remains the primary tool for the identification and diagnosis
of dementia and specific cognitive deficits (Harper 2014; Health
Quality Ontario 2014; NICE 2018; Panegyres 2016; Robinson
2015). There are now several validated cognitive assessments tools
available for screening, diagnosis and monitoring of cognitive dis-
orders (Velayudhan 2014); thus, standard assessment practice is
currently highly variable across theUK (CareQualityCommission
2014; Walker 2017). Choice of cognitive assessment tool is de-
pendent on clinician and area, which introduces significant vari-
ations in dementia assessment practices nationally (Care Quality
Commission 2014; Walker 2017), and worldwide due to lack of
standardisation of tests across languages, literacy levels, and cul-
tures (Kalaria 2010). Furthermore, there is a lack of consistent
international guidance on the assessment and management of de-
mentia, which has the potential to introduce further geographical
disparities in care (Ngo 2015).Certainly, concerns have been raised
regarding the widespread use of common assessment tools, partic-
ularly for the assessment of mild cognitive impairment, where the
sensitivity is low (Nasreddine 2005). Therefore, clarity is urgently
required on the most appropriate and valid cognitive assessment
tool for the early identification and monitoring of cognitive dis-
orders.
Cognitive impairment is frequently not identified in routine as-
sessments in primary care; cognitive decline is not recognised in
up to 76% of patients (Chodosh 2004; Ganguli 2004; Lin 2013;
Valcour 2000). The majority of these patients will be diagnosed
in the later stages of disease (Lin 2013). Early identification of
dementia can often be the gateway to accessing crucial support
and care services available to patients and their carers (Aminzadeh
2007; de Vugt 2013).
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The Addenbrooke’s Cognitive Examination (ACE) was originally
designed as a brief, bedside cognitive screen thatwas specifically de-
veloped to incorporate tests ofmemory, visuospatial, and executive
function, with the ability to detect early dementia and differentiate
Alzheimer’s disease from frontotemporal and Parkinson’s dementia
(Larner 2014; Mioshi 2006; Noone 2015; Velayudhan 2014). A
number of limitations were identified with the ACE, and this was
updated to improve sensitivity, ease of administration, and to facil-
itate translation and cross-cultural use as the Addenbrooke’s Cog-
nitive Examination Revised (ACE-R) (Mioshi 2006). The ACE-
R demonstrated significantly better sensitivity and specificity than
the ACE (Larner 2014;Mioshi 2006), but further weaknesses were
identified, including ceiling effects to several questions, confound-
ing to verbal repetition by poor hearing, and difficulty translat-
ing for cross-cultural use (Hsieh 2013; Velayudhan 2014). The
ACE-III was developed to address these limitations (Hsieh 2013).
The ACE-III has subsequently been translated into a number of
languages, including Portuguese, Spanish, and Egyptian Arabic
(Mirza 2017).
The ACE-III is a brief, bedside, cognitive screening test that
takes approximately 15 to 20 minutes to deliver; it encompasses
five major cognitive domains: attention, memory, language, visu-
ospatial function, and verbal fluency (Hsieh 2013; Noone 2015;
Velayudhan 2014). It is composed of 21 cognitive tasks and has
a total score of 100, where the common cut-offs for dementia
and MCI are considered at scores lower than 82 and 88, respec-
tively (Hsieh 2013; Velayudhan 2014). Studies have demonstrated
good sensitivity (93% to 100%) and specificity (96% to 100%)
at these cut-offs, but pooled estimates are lacking (Noone 2015;
Velayudhan 2014). Themini-ACEwas derived as a shorter version
of the ACE-III, which takes under five minutes to perform, but
maintains good sensitivity (61%, 85%), and specificity (100%,
87%), at established thresholds of 21 and 25 respectively (Hsieh
2015). Furthermore, the mini-ACE can be used to distinguish
between Alzheimer’s disease and other forms of dementia (i.e.
frontotemporal dementia, primary progressive aphasia, and cor-
ticobasal syndrome) (Hsieh 2015). The mini-ACE is a 30-point
scale covering four cognitive domains: orientation, memory, lan-
guage and visuospatial function. It can be used in a variety of clin-
ical settings and is easily translated (Hsieh 2015). The mini-ACE
is designed to be used as a brief screening tool to facilitate refer-
ral for formal neuropsychological testing and cognitive assessment
(Hsieh 2015).
Clinical pathway
Patients presenting with cognitive decline are encountered in a
variety of healthcare settings, including general practice, inpatient
settings, outreach, and community services (Creavin 2016; Davis
2015; Robinson 2015). National screening for dementia is not
currently recommended for all people aged over 65 (NICE 2018).
However, the Government’s Commissioning for Quality and In-
novation (CQUIN) has recently expressed support for targeted
screening of at-risk groups in accident and emergency departments
and general practice (Alzheimer’s Research UK 2017). This iden-
tifies patients presenting in these settings that are more likely to be
at risk of dementia, and prompts further questioning and inves-
tigation (Alzheimer’s Research UK 2017). Cognitive assessment
tools are becoming increasingly important as part of this targeted
screening approach in identifying who should be referred for fur-
ther specialist assessment.
Patients with dementia typically present with a progressive his-
tory of declining cognitive function over a period of months to
years, which eventually results in loss of daily function for that
individual (Creavin 2016; Davis 2015; Robinson 2015). Current
guidance from the National Institute for Health and Care Ex-
cellence (NICE) advocates early referral to a specialist memory
service when a diagnosis of dementia is suspected (NICE 2018).
Brief cognitive assessments, specifically designed for community
and general practice, are available to assist community practition-
ers in deciding where referral may be appropriate (NICE 2018;
Velayudhan 2014). A diagnosis of dementia should only be made
following a comprehensive, specialist assessment (NICE 2018).
Therefore, all patients with a suspected diagnosis of dementia
should undergo formal cognitive testing at the initial specialist
assessment, and this should include measures of: attention and
orientation, short- and long-term memory, praxis, language and
executive function (NICE 2018). Cognitive assessment should be
undertaken alongside a full history, collateral history, mental state
examination, physical examination, medication review, laboratory
investigations, and brain imaging (NICE 2018; Robinson 2015).
A diagnosis of dementia requires deficits in at least two cognitive
domains, with an impact on the patient’s ability to carry out ac-
tivities of daily living (Robinson 2015).
Patients with MCI typically present with cognitive decline or
change in memory, and can be identified in primary, secondary,
and community care settings. The key factor which distinguishes
MCI fromdementia is the absence of functional impact on day-to-
day living (Petersen 2004). In order to confirm a diagnosis ofMCI,
patients must have both subjective and objective cognitive de-
cline, in addition to remaining functionally independent (Petersen
2004). Cognitive assessment tools form an integral component
in identifying any objective cognitive deficits. It is important to
distinguish MCI from dementia, as it has clinically relevant con-
sequences for therapeutic management. Where patients with mild
dementia would be eligible for initiation of acetylcholinesterase
inhibitors, there is currently no evidence to support their use in
the treatment of MCI (NICE 2018). Ensuring the correct identi-
fication and diagnosis of individuals is a crucial step in the clinical
pathway for these patients.
Alternative test(s)
There are numerous cognitive assessment tools available for the
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screening and diagnosis of dementia, and these have been assessed
in a number of previous reviews (Tsoi 2015; Velayudhan 2014).
The Mini Mental State Examination (MMSE) is amongst one of
the more widely used tests, but its use has been limited in recent
years due to availability, and concerns about lack of sensitivity (Tsoi
2015). The findings of a recent Cochrane Review do not support
the use of the MMSE to identify patients with MCI who could
develop dementia (Arevalo-Rodriguez 2015), butCreavin and col-
leagues stated it can be used to support the diagnosis of dementia
in primary care (Creavin 2016). The Montreal Cognitive Assess-
ment (MoCA) has recently been evaluated in a Cochrane Review
for the diagnosis of dementia (Davis 2015). The MoCA was able
to correctly identify dementia in 94% of cases, across all settings,
but was limited by a high rate of false positive diagnoses (Davis
2015). Furthermore, the evidence supporting the use of MoCA
was only in secondary care settings, which limits the generalisabil-
ity of these findings to primary care (Davis 2015). The Informant
Questionnaire on Cognitive Decline in the Elderly (IQCODE) is
questionnaire based on informant responses to support a diagnosis
of dementia (Harrison 2016). The IQCODE has good sensitivity,
but was found to lack sufficient specificity for diagnosing demen-
tia across several healthcare settings (Harrison 2016). A full list
detailing the currently available Cochrane diagnostic test accuracy
(DTA) reviews for neuropsychological assessments in dementia is
available in Table 1.
Rationale
A diagnosis of dementia still carries much stigma and fear in mod-
ern society (Aminzadeh 2007; de Vugt 2013). Despite increasing
research, sensitive diagnostic tests and curative treatments remain
elusive. Given the absence of an available cure, the consequences
of a dementia diagnosis are profound and have an enormous im-
pact on the patient, their family, and support network (Aminzadeh
2007; Davis 2015; de Vugt 2013). A high level of test sensitiv-
ity is important to minimise the rate of false negative diagnoses,
which can prevent or delay access to available treatments and sup-
port services, and potentially worsen the dementia state and carer
strain, and evoke loss of confidence in care services (de Vugt 2013).
Similarly, a high test specificity will minimise the number of false
positive diagnoses. A false positive diagnosis of dementia could
cause serious psychological harm, and lead to unnecessary further
investigations and treatments for a patient and their carers (de
Vugt 2013). If clinical practitioners had access to a screening test
with high sensitivity and specificity, it would reduce the negative
consequences outlined above, and facilitate the timely delivery of
support and available treatments (de Vugt 2013).
In summary, there have been a number of reviews of the ACE
and ACE-R (Crawford 2012; Larner 2014; Tsoi 2015), but no
comprehensive review of later versions of the ACE (ACE-III and
mini-ACE) has been carried out to date. Therefore, a Cochrane
Review is required to assess the validity of the ACE-III and mini-
ACE across all the available evidence, cut-off scores, settings in
which the tools have been validated, and the quality of the ev-
idence to date. In particular, the mini-ACE and ACE-III have
shown promising results in a number of studies, and so may prove
more sensitive and specific tests for the early detection of cognitive
disorders, with the ability to distinguish between dementia sub-
types (Hsieh 2013; Hsieh 2015). Correct, early identification and
stratification of patients with dementia can result in better clini-
cal outcomes, through the early initiation of available therapeutics
and support services for patients and carers (Creavin 2016; Davis
2015; de Vugt 2013).
O B J E C T I V E S
To assess the diagnostic test accuracy of the Addenbrooke’s Cogni-
tive Examination-III (ACE-III) and the mini-ACE, for the screen-
ing of all-cause dementia, dementia subtypes (Alzheimer’s disease,
vascular dementia, frontotemporal dementia, Lewy body demen-
tia), and mild cognitive impairment, across all healthcare settings
at all prespecified thresholds.
Secondary objectives
1) To identify the quality and quantity of the research evidence on
the diagnostic test accuracy of the ACE-III and mini-ACE for the
assessment of all-cause dementia, dementia subtypes (Alzheimer’s
disease, vascular dementia, frontotemporal dementia, Lewy body
dementia), and mild cognitive impairment, across all healthcare
settings at all reported thresholds.
2)To identify sources of heterogeneity (age, sex, education, severity
or stage of the target condition, operator characteristic of the index
test and reference standard) in the included studies.
3) To identify gaps in the evidence where further research is re-
quired.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will consider cross-sectional studies for inclusion in this re-
view, where the index test is administered alongside expert confir-
mation for reference. Comparative studies between dementia sub-
types (i.e. Alzheimer’s disease and frontotemporal dementia), or
comparing the index tests with an alternative (i.e. theMiniMental
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State Examination (MMSE), the Montreal Cognitive Assessment
(MoCA)), will also be considered for inclusion if an appropriate
reference standard is present, but only data on the ACE-III and
mini-ACE will be included. We anticipate the majority of studies
will follow a cross-sectional design.
We will not include case control studies in this review due to the
high risk of bias in these studies. Nested case control studies, where
cases and controls are selected from the cohort population,will also
be considered for inclusion. Delayed verification or longitudinal
studies will not be included in this review.
Studies with small number of cases (less than 10), will not be
considered for inclusion due to their associated high risk of bias.
Participants
Patients presenting with cognitive decline, undergoing cognitive
testing in primary or secondary care, will be suitable for inclusion.
Studies which included participants with a comorbidity associated
with cognitive impairment (motor neurone disease (MND), mul-
tiple sclerosis (MS), Parkinson’s disease, brain injury/tumour/in-
fection), but not a primary dementia diagnosis, will be excluded if
these participants comprised more than 20% of the study popula-
tion. In addition, studies which included participants with known
substance abuse or medication use known to affect cognition will
be excluded if these participants comprised more than 20% of the
study population. Studies withmixed populations will be excluded
from this review, if they comprised more than 20% of the study
population.
Index tests
The ACE-III and mini-ACE only will be considered for screen-
ing accuracy. There are other versions, such as the Addenbrooke’s
Cognitive Examination and the Addenbrooke’s Cognitive Exam-
ination Revised (ACE-R), however the ACE-III and mini-ACE
have superseded these older, previous versions and thus repre-
sent the most up-to-date versions of the tool. Threshold scores
of 82 and 88 for the ACE-III (Velayudhan 2014), and 21 and
25 for the mini-ACE (Hsieh 2015), have been reported con-
sistently in the literature, and are currently used convention-
ally in clinical practice. Therefore this review will investigate
the summary sensitivity and specificity values at these prede-
fined thresholds. The ACE-III and mini-ACE have been trans-
lated into several languages, and all studies assessing the screen-
ing accuracy of translated versions of the ACE-III and mini-
ACE will be considered for inclusion. The ACE-III and mini-
ACE tools are available at http://dementia.ie/images/uploads/
site-images/ACE-III Administration (UK).pdf and https://s3-
eu-west-1.amazonaws.com/pstorage-karger-594308543098/
6990263/450784 sm1.pdf, respectively.
Target conditions
The target conditions to be detected by the ACE-III or mini-
ACE are as follows: all-cause dementia (undifferentiated), specific
dementia subtypes (Alzheimer’s disease, vascular dementia, fron-
totemporal dementia, Lewy body dementia), and mild cognitive
impairment (MCI). All-cause dementia has been included as a tar-
get condition, as it is anticipated that some studies will not have
differentiated between dementia subtypes. In addition, the ACE-
III and mini-ACE are being evaluated as screening tests, therefore,
understanding the ability of the test to identify undifferentiated
cognitive impairment for onward specialist referral for subtype and
classification would be of relevance to primary care practitioners.
Reference standards
At present, there is no gold-standard test for the confirmation of
MCI, dementia, or subtype. In current practice, dementia and
MCI are confirmed by an appropriately qualified clinical specialist
or expert (i.e. neurologist or psychiatrist), using internationally
developed and validated criteria. The reference standard for this
review is a clinical confirmation of dementia orMCI using disease-
specific reference standards developed by a consensus group or
accredited body, as follows.
• Undifferentiated dementia: Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition and Fifth Edition
(DSM-IV and DSM-5) (American Psychiatric Association 2000;
American Psychiatric Association 2013), International
Classification of Diseases 10th Revision and 11th Revision
(ICD-10 and ICD-11) (World Health Organization 2010;
World Health Organization 2018).
• Alzheimer’s disease: NINCDS/ADRDA (McKhann 1984),
ICD-10 and ICD-11 (World Health Organization 2010; World
Health Organization 2018), DSM-IV and DSM-5 (American
Psychiatric Association 2000; American Psychiatric Association
2013), National Institute on Aging and the Alzheimer’s
Association (NIA/AA) (McKhann 2011).
• Vascular dementia: NINDS-AIREN (Roman 1993), DSM-
IV and DSM-5 (American Psychiatric Association 2000;
American Psychiatric Association 2013), ICD-10 and ICD-11
(World Health Organization 2010; World Health Organization
2018).
• Frontotemporal dementia: Lund-Manchester criteria (Lund
1994), NINDS (Rascovsky 2011).
• Lewy body dementia: International consensus criteria
(McKeith 2006)
• MCI: NIA/AA (McKhann 2011), DSM-IV and DSM-5
(American Psychiatric Association 2000; American Psychiatric
Association 2013), Mayo (Petersen 2013), Petersen (Petersen
2004).
• Post-stroke dementia (DSM-IV and DSM-5 (American
Psychiatric Association 2000; American Psychiatric Association
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2013), ICD-10 and ICD-11 (World Health Organization 2010;
World Health Organization 2018).
The presence of the disease will need to be confirmed using one
of these recognised criteria by an appropriately qualified specialist,
expert, or consensus group in order for a study to be included in
this review. Radiological and biochemical investigations are often
used alongside clinical assessment to confirm dementia or MCI,
however, studies which rely on imaging and biochemical investi-
gations alone, without clinical assessment, will be excluded from
this review.
Studies using a histopathological diagnosis of dementia as a refer-
ence standard will not be suitable for inclusion as this is a post-
mortem diagnosis.
Search methods for identification of studies
Search methods will be carried out in accordance with Chapter 7
of the Cochrane Handbook for Systematic Reviews of Diagnostic Test
Accuracy. The search strategy will be determined in conjunction
with the Information Specialist at the Cochrane Dementia and
Cognitive Improvement Group (CD-CIG).
Electronic searches
We will search MEDLINE (OvidSP), Embase (OvidSP), BIO-
SIS (Ovid), Science Citation Index (ISI Web of Knowledge),
PsycINFO (Ovid), LILACS (Bireme), ALOIS (specialised register
of the CD-CIG), and the Cochrane Register of Diagnostic Test
Accuracy Studies, using a structured search strategy appropriate
for each database. Controlled vocabulary, such asMeSH terms and
EMTREE, will be used where appropriate. The search will not
be restricted by sampling frame, setting, or language. Translation
services will be used as required. A single researcher, with exten-
sive experience in systematic reviewing, will perform subsequent
searches. The MEDLINE search strategy can be seen in Appendix
1.
Searching other resources
We will review the reference lists of all included studies. We will
also search the following additional databases.
• Database of Abstracts of Reviews of Effects (DARE):
www.york.ac.uk/inst/crd/crddatabases.html (updated to 2015).
• Health Technology Assessment (HTA) Database:
www.cochrane.org/about-us/evidence-based-health-care/
webliography/books/hta, via the Cochrane Library.
• Aggressive Research Intelligence Facility (ARIF):
www.arif.bham.ac.uk (updated to 2018).
We will use the ’related articles’ feature of PubMed to search for
additional studies. Citation databases, such as Science Citation
Index andScopus, will be searchedusing key studies to identify any
additional relevant studies.Wewill search grey literature, including
conference proceedings, theses, and PhD abstracts. We will not
perform handsearching, in accordance with the generic protocol
(Davis 2013). Research groups involved in previously published or
ongoing research on the ACE-III or mini-ACE will be contacted
to identify any relevant, unpublished data.
Data collection and analysis
Selection of studies
The eligibility criteria are as follows.
Inclusion criteria:
• community, primary and secondary care services;
• patients presenting with cognitive decline;
• cross-sectional, comparative, or nested case-control studies;
• studies utilising the ACE-III or mini-ACE as the index test;
• presence of a referenced standard as specified above.
Exclusion criteria:
• patients with a diagnosis of dementia at presentation;
• patients with comorbidity associated with cognitive
impairment, motor neurone disease (MND), multiple sclerosis
(MS), Parkinson’s disease, brain injury, tumour, infection;
• patients with presence of substance abuse, or medication
use known to affect cognition;
• case-control studies, longitudinal or delayed-verification
studies;
• small sample size (less than 10 participants);
• studies utilising older versions of the tool (ACE, ACE-R);
• absence of a reference standard as specified above.
Two review authors (LCB, APB) will independently screen eligible
articles based on title and abstract. After this, full papers will be
reviewed independently by at least two authors (LCB, APB, VJH)
for inclusion in the review. Disagreements will be resolved by dis-
cussion, and if they remain unresolved despite this, will be referred
to an arbitrator within the study team (VJH, TGR). Where dis-
agreements are not resolved, the default position will be to include
the study in the review. The study selection process will be detailed
in a PRISMA flow diagram.
Data extraction and management
A study-specific proforma will be developed, and data will be ex-
tracted on the following: study characteristics (setting, type, num-
ber of participants, diagnostic criteria, language, index test), de-
mographics of the participants (age, gender, diagnosis, comorbidi-
ties), study quality assessment, and heterogeneity. The proforma
will be piloted on ten diagnostic studies, before use in the review.
The data that will be collected with the study proforma are de-
tailed in Appendix 2.
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Data will be extracted independently by two review authors (LCB,
APB). Test accuracy data will be dichotomised if required, and
cross-tabulated in two-by-two tables of index test results (posi-
tive or negative) against the target condition (positive or nega-
tive). Disagreements between authors on data extraction will be
resolved initially by discussion, and if this not possible referred
to a third author (VJH, TGR) for arbitration. The results will be
extracted directly into tables in Review Manager version 5.3 soft-
ware (Review Manager 2014).
For each included study, we will outline the flow of the participant
(i.e. number recruited, included and assessed), in a flow diagram.
Assessment of methodological quality
Methodological quality will be assessed independently by two au-
thors (LCB, APB), using the Quality Assessment Tool for Diag-
nostic Accuracy Studies (QUADAS-2) (Whiting 2011). The tool
consists of four domains: patient selection, index tests, reference
standard, and patient flow. Each domain will be assessed in terms
of risk of bias, and the first three domains will be considered in
terms of applicability. The QUADAS-2 tool will be piloted on
the first five studies included in the review. Where there is poor
agreement between the two review authors, the tool will be revised
and re-piloted. Disagreements between authors on study quality
will be resolved initially by discussion, and if this not possible
referred to a third author (VJH, TGR) for arbitration. Studies
will be graded as being at high, medium or low risk of bias, with
a narrative summary presented for each study. The QUADAS-2
tool is available in Appendix 3, and the anchoring statements in
Appendix 4. The use of the reference standard and index tests are
not completely independent of one another, and this introduces
a risk of incorporation bias. Included studies will be assessed for
the presence of incorporation bias.
The STARdem tool (Noel-Storr 2014) has been recently devel-
oped to report the quality of study reporting in dementia. In
addition to reporting methodological quality, this review will
also report on the quality of study reporting using this check-
list (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4115600/
table/T3/?report=objectonly).
Statistical analysis and data synthesis
The target condition comprises three categories: 1) undiffer-
entiated (all-cause) dementia, 2) specific dementia subtypes
(Alzheimer’s disease, vascular dementia, frontotemporal demen-
tia, Lewy body dementia), and 3) MCI. The index test comprises
two categories, ACE-III, or the mini-ACE. The setting also com-
prises three categories: community, primary, and secondary care.
A separate meta-analysis will be required for each index test, in
each study setting, and for each of the above target conditions.
Given that the ACE-III and mini-ACE have only been developed
recently, it is possible that there will be insufficient study numbers
for meta-analysis across these conditions and settings. If there are
insufficient studies for meta-analysis, a descriptive summary of the
numerical results will be provided.
For all included studies (cross-sectional), we will extract data in bi-
nary two-by-two tables (binary test results cross-classified with the
binary reference standard) and this will be used to calculate sensi-
tivities and specificities, with 95% confidence intervals. Individual
study results will be presented graphically by plotting estimates of
sensitivities and specificities in a forest plot and receiver operating
characteristic (ROC) curves. We will perform analyses using Re-
view Manager 5 software for Windows. As outlined above, prede-
fined thresholds of 82 and 88 for the ACE-III (Velayudhan 2014),
and 21 and 25 for the min-ACE (Hsieh 2015) will be used to cal-
culate summary sensitivity and specificity values at each threshold.
Each study included in this review can contribute to one or more
thresholds, and studies which do not report any of these thresholds
will be excluded from this review. Graphical presentations will be
undertaken for all predefined thresholds reported in the included
studies.
Summary analysis will be undertaken using a bivariate random-
effects approach, based on pairs of sensitivity and specificity to cal-
culate pooled estimates of: sensitivity, specificity, positive and neg-
ative predictive values, positive and negative likelihood ratios, and
95% confidence intervals. We will not undertake univariate anal-
yses if there are insufficient studies to calculate summary statistics,
due to a risk of under-estimating test accuracy (Deeks 2001). In
this instance, results will be presented for each study in tables and
forest plots. Summary analysis will be performed using MetaDTA
software (MetaDTA 2018). TheMetaDTA app is evolving tomeet
the needs of end-users. The current beta version has new func-
tionality and further modifications are planned. However, it is not
guaranteed that all the analytical options required for this review
will be incorporated by the time we come to analysis. We propose
that we use MetaDTA in the first instance, to explore the data. If
needed, we will use macros developed for use in SAS software for
more sophisticated analyses.
Investigations of heterogeneity
As outlined above, it is unlikely that there will be sufficient studies
for each of the categories of target condition, index test, and setting
formeta-analysis. Therefore, there are unlikely to be sufficient data
for heterogeneity analyses. In line with previous Cochrane DTA
reviews of neuropsychological tests, we anticipate there will be a
number of sources of heterogeneity in the studies identified for
review (Creavin 2016; Davis 2013; Davis 2015; Harrison 2016).
We have identified key factors to be explored in a prespecified
heterogeneity analysis, and these are outlined below.
Case mix
The casemix of the populations included in the studies could enter
significant heterogeneity in terms of age, dementia diagnosis, spe-
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cific populations versus unselected populations, and the severity
or stage of the dementia diagnosis. The test properties are likely to
differ in younger compared to older populations. In studies where
less than 20% of the population is under 65 years of age, they
are not likely to be representative of this population, and sensitiv-
ity analyses will be carried out to determine the effect of remov-
ing these studies on the summary results. Finally, the majority of
studies will enrol adults from an unselected population. However,
where studies enrol a specific or limited population, a sensitivity
analysis will be conducted to identify the effect of removing these
studies on summary results.
Reference standard criteria
An important source of heterogeneity, and a key component of
methodological quality, is the process bywhich the cases of demen-
tia or MCI are confirmed and subclassified. Data will be collected
on this process, including which reference standard or criteria were
used, whether it was by consensus meeting, individual assessment,
or algorithm, and whether imaging or biochemical investigations
were included. The quality of this process will be assessed at study
level using the QUADAS-2 tool.
Technical features of the index tests
Several thresholds have been reported in the literature for both the
ACE-III and mini-ACE, however, the two most consistent levels
which are currently used in clinical practice have been selected
for analysis. Analyses will be conducted for all of the predefined
thresholds for each test.
Heterogeneity will be investigated informally in the first instance
through visual examination of forest plots of sensitivities and speci-
ficities and through visual examination of the ROC plot of the
raw data. If sufficient data are present, formal investigation of the
sources of heterogeneity will be explored through subgroup anal-
yses, and regression analyses with up to ten studies per covariate.
Assistance for subgroup and regression analyses will be provided
by a statistician (CPN).
Sensitivity analyses
Sensitivity analyses will be undertaken to determine the effects of
excluding low-quality studies on analyses. Primary analysis will
include all studies, and sensitivity analyses will exclude studies felt
to be at high risk of bias using the QUADAS-2 tool, and studies
identified as less appropriate for inclusion (i.e. where there was
unresolved disagreement between authors). ROC curves, forest
plots, and summary statistics will be re-run with the exclusion of
studies at high risk of bias, and compared to the original analyses.
Sensitvity analysis will be performed using MetaDTA software
(MetaDTA 2018).
Assessment of reporting bias
We will not explore reporting bias in this review, as current quan-
titative methods for exploring reporting bias are not well estab-
lished for studies of DTA. Specifically, funnel plots of the diag-
nostic odds ratio versus the standard error of this estimate will not
be considered.
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A D D I T I O N A L T A B L E S
Table 1. Cochrane reviews of DTA studies for neuropsychological assessment tools in dementia
Cognitive Test Available Community Primary Secondary
Mini-Cog Y x x Protocol
IQCODE Y x x x
AD-8 Protocol x x x
MMSE Y x x x
MoCA Y x x
IQCODE = Informant Questionnaire on Cognitive Decline in the Elderly; MMSE = Mini-Mental State Examination; MoCA =
Montreal Cognitive Assessment
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A P P E N D I C E S
Appendix 1. Search strategy
The search strategy uses two concepts: index test/s and populations of interest. The search was devised and then tested on a set of
known studies. All known studies were identified by the search.
1. Addenbrooke* Cognitive Exam*.ti,ab.
2. ACE.ti,ab.
3. ACE-r.ti,ab.
4. Mini-Addenbrooke* Cognitive Exam*.ti,ab.
5. mini-ACE.ti,ab.
6. ACE-III.ti,ab.
7. or/1-6
8. ((cognit$ or memory or cerebr$ or mental$) adj3 (declin$ or impair$ or los$ or deteriorat$ or degenerat$ or complain$ or disturb$
or disorder$)).ti,ab.
9. (forgetful$ or confused or confusion).ti,ab.
10. MCI.ti,ab.
11. AMCI.ti,ab.
12. ARCD.ti,ab.
13. SMC.ti,ab.
14. CIND.ti,ab.
15. BSF.ti,ab.
16. AAMI.ti,ab.
17. MD.ti,ab.
18. LCD.ti,ab.
19. QD.ti,ab.
20. AACD.ti,ab.
21. MNCD.ti,ab.
22. MCD.ti,ab.
23. (“N-MCI” or “A-MCI” or “M-MCI”).ti,ab.
24. minor neurocognitive disorder.ti,ab.
25. Cognitive Dysfunction/
26. Cognition Disorders/
27. or/8-26
28. exp DEMENTIA/
29. major cognitive disorder.ti,ab.
30. alzheimer*.ti,ab.
31. dement*.ti,ab.
32. ((lewy adj2 bod*) or LBD or DLB).ti,ab.
33. (FTLD or frontotemp*).ti,ab.
34. or/28-33
35. 27 or 34
36. 7 and 35
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Appendix 2. Study data to be included in the data collection proforma
1. Bibliographic details of primary paper: author, title of study, year, and journal.
2. Details of index test: method of ACE-III and mini-ACE administration, including who administered and interpreted the test,
and their training. Thresholds used to define positive and negative tests.
3. Reference standard: reference standard used. Method of reference standard administration, including who administered the test
and their training.
4. Study population: number of subjects. Age. Gender. Other characteristics (e.g. ApoE status). Settings: community, primary care,
secondary care outpatients, and secondary care inpatients and residential care. Participant recruitment. Sampling procedures. Time
between index test and reference standard. Proportion of people in sample with dementia. Subtype and stage of dementia if available.
MCI definition used (if applicable). Duration of follow-up in delayed verification studies. Attrition and missing data.
Appendix 3. QUADAS-2 tool
DOMAIN PARTICIPANT
SELECTION
INDEX TEST REFERENCE
STANDARD
FLOW AND TIMING
Description Describe methods
of participant selection:
describe included partic-
ipants (prior testing, pre-
sentation, intended use
of index test and setting)
:
Describe the index test
and how it was con-
ducted and interpreted
Describe the reference
standard and how it
was conducted and in-
terpreted
De-
scribe any participants
who did not receive the
index test(s) and/or ref-
erence standard or who
were excluded from the
2x2 table (refer to flow
diagram): describe the
time interval and any in-
terventions between in-
dex test(s) and reference
standard:
Signalling questions
(yes/no/unclear)
Was a consecutive or ran-
dom sample of partici-
pants enrolled?
Were the index test re-
sults interpreted without
knowledge of the results
of the reference stan-
dard?
Is the reference standard
likely to correctly classify
the target condition?
Was there an appropri-
ate interval between in-
dex test(s) and reference
standard?
Was a case-control de-
sign avoided?
If a threshold was used,
was it prespecified?
Were the reference stan-
dard results interpreted
without knowledge of
the results of the index
test?
Did all participants re-
ceive a reference stan-
dard?
Did the study avoid in-
appropriate exclusions?
Did all participants re-
ceive the same reference
standard?
Were all participants in-
cluded in the analysis?
Risk of bias:
(high/low/ unclear)
Could the selection of
participants have intro-
duced bias?
Could the conduct or in-
terpretation of the in-
dex test have introduced
Could the reference stan-
dard, its conduct, or its
interpretation have in-
Could the participant
flow have introduced
bias?
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(Continued)
bias? troduced bias?
Concerns regarding ap-
plicability:
(high/low/ unclear)
Are there concerns that
the included participants
do not match the review
question?
Are there concerns that
the index test, its con-
duct, or interpretation
differ from the review
question?
Are there concerns that
the target condition as
defined by the reference
standard does not match
the review question?
Appendix 4. QUADAS-2 anchoring statements
We have adapted the core anchoring statements provided for use with the QUADAS-2 tool. The original anchoring statements were
determined froma twodaymulti-disciplinary groupmeeting, designed for usewith theQUADAS-2 tool to support decisions concerning
methodological quality for studies included in systematic reviews. Some of the original anchoring statements are less applicable to DTA
reviews of neuropsychological assessments (ref MMSE review, etc.). Thus, two authors (LCB, APB) adapted the original anchoring
statements specifically for this review, and these revised statements were reviewed by the co-authors. The tool and anchoring statements
will be piloted against the first five studies included in this review and if there is poor inter-rater agreement of study methodological
quality, the statements will be revised and re-piloted until good agreement between raters is achieved.
Domain 1: participant selection
Was a consecutive or random sample of participants enrolled?
The method of sampling should be stated or described. Non-random sampling, sampling based on volunteers, or selecting participants
from a clinic or research population is more likely to introduce a high risk of bias and should be classified as such, whereas consecutive
or random sampling are least likely to introduce bias, and should be classified as low risk.
Weighting: high risk
Was a case control design avoided?
Case control designs are associated with a high risk of bias and should be excluded from this review. However, nested case control
studies (where the study population is drawn from a larger pool of patients from an interventional or cohort study) are associated with
a lower risk of bias, and are considered for inclusion in this review. Nested-case control studies should be classified as a high risk of bias,
and any study which increases or decreases the proportion of patients with the target condition (i.e. enrichment from secondary care
settings) should be classified as high risk of bias.
Weighting: high risk
Did the study avoid inappropriate exclusions?
Studies which do not explicitly detail exclusion criteria will be classified as unclear risk of bias, but study authors will be contacted for
this information. Studies which clearly detail all exclusions, and are felt to be appropriate by review authors will be classified as low
risk of bias. Exclusion criteria must be justified for studies which exclude difficult to diagnose groups. It is anticipated that there will
be common exclusion criteria (e.g. substance misuse, other degenerative disease) for included studies, which are listed in the protocol.
Community studies with extensive exclusion criteria should be classified at high risk of bias. Post-hoc exclusions will be classified as
high risk of bias.
Weighting: high risk
Domain 2: index test
Could the conduct or interpretation of the ACE-III/mini-ACE have introduced bias?
Studies will be considered low risk where the investigators conducting the ACE-III/mini-ACE were blinded to the participant’s diagnosis
or were independent from the study and without knowledge of the reference standard. Studies which explicitly state this do not require
further information on the blinding or independence of the process and will be classified as low risk of bias. Studies will be classified
as low risk of bias if the ACE-III or mini-ACE were conducted prior to the reference standard.
Weighting: high risk
Were the ACE-III/mini-ACE thresholds pre-specified?
A study will be classified as high risk of bias where the authors set the optimal cut off point post-hoc using their own study data. Studies
that do not use defined thresholds, and use an alternative methods of analysis will be classified as not applicable.
Weighting: high risk
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Were sufficient data on ACE-III or mini-ACE application given for the test to be repeated in an independent study?
For studies to be classified at low risk of bias, information on the method of administration (i.e. appropriately qualified/trained), and
the language of assessment should be provided. If a translated version of the ACE-III or mini-ACE is used, details of the scale and on
the validation process will be needed to be classified at low risk of bias.
Weighting: low risk
Domain 3: reference standard
Is the reference standard likely to correctly classify the target condition?
Studies using reference standards listed in the protocol or a recognised/validated reference standard will be considered at low risk of
bias. Studies using a reference standard not recognised by the authors or the Cochrane Dementia and Cognitive Improvement Group,
will be classified at high risk of bias.
Weighting: high risk
Were the reference standard results interpreted without knowledge of the results of the ACE-III/mini-ACE?
For a study to be classified as low risk of bias, the investigators would need to have interpreted the reference standard results independently
to those of the ACE-III or mini-ACE. Studies which explicitly state this do not require further information on the blinding or
independence of the process and will be classified as low risk of bias. If the ACE-III or mini-ACE were used as part of the clinical
dementia/MCI assessment as reference standard, this will be considered to be at high risk of bias.
Weighting: high risk
Were sufficient information on the method of dementia/MCI assessment given for the assessment to be repeated in an independent study?
The method of dementia assessment will need to be described to be considered at low risk of bias. Information should be provided
on: the training and expertise of the assessor, whether it was by individual, consensus, or algorithm, and the use of neuropsychological,
laboratory and neuroimaging assessments.
Weighting: high risk if not described
Domain 4: patient flow and timing
Was there an appropriate interval between the ACE-III or mini-ACE and the reference standard?
Ideally, the reference standard and ACE-III or mini-ACE would be completed on the same day or visit, to minimise changes or
fluctuations in cognition over time. However, dementia is slowly progressive and an irreversible condition so delay is unlikely to
introduce significant bias. However, patients with MCI can revert to normal cognition, progress, or remain stable over time. Therefore,
a time delay could affect the measured cognitive status of these individuals, however the duration over which this might occur is not
known. We have therefore set an arbitrary cut off of one month for studies assessing MCI. Longitudinal and delayed verification studies
are excluded from this review.
Weighting: low risk
Did all subjects receive the same reference standard?
Where the clinical assessment or reference standard differs between participants in a study, this will be classified at high risk of bias.
Participants who score test positive on the ACE-III or mini-ACE who are subject to further testing above other participants will be
classified at high risk of bias.
Weighting: high risk
Were all participants included in the final analysis?
Attrition will vary with study design, but drop-out rates and missing data should be reported and accounted for. Where attrition is
higher than expected (greater than 20% of study cohort), these studies will be classified at high risk of bias.
Weighting: high risk
Applicability
Were those included representative of the general population?
The included participants should match the intended population as described in the review protocol. The setting of the included study
will need to be taken into account, and the prevalence of the disease within that setting. Included participants should be presenting
with cognitive decline, but the disease status should not be known at the time of administering the ACE-III or mini-ACE. Studies will
be classified as low applicability where they included a highly selected population, or sub-group.
Was the ACE-III or mini-ACE performed consistently and in a manner similar to its use in clinical practice?
Variation in the length, structure, language, and/or administration of the ACE-III or mini-ACE not in line with the original description
of the ACE-III or mini-ACE may affect the applicability. Included studies will be judged against the original description of the ACE-
III or mini-ACE.
Was the clinical diagnosis of dementia or MCI (reference standard) made in a manner similar to current clinical practice?
Although studies may have utilised a validated reference standard for the diagnosis of dementia or MCI, there is a risk that the reference
standard may over- or under-diagnose the proportion of participants with the disease. If there are concerns that the reference standard
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diagnosed a smaller or larger than anticipated proportion of participants given the specified clinical population, this would be rated as
poor applicability.
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